<DOC>
	<DOCNO>NCT01797484</DOCNO>
	<brief_summary>The aim RIMINI-Trial examine effect Ranolazine ischemic myocardium acute myocardial ischemia . A pilot-trial Venkatamaran et al . recently demonstrate , area ischemic myocardium patient stable coronary artery disease reduce Ranolazine-treatment2 . This effect show significantly reduce area atypical dysfunctional myocardium SPECT-examinations . The dimension myocardial damage ( i.e . area ischemic myocardium ) directly relate rate complication ( i.e . left-ventricular pump failure , malignant arrhythmia ) grade Rehabilitation daily life ( i.e . persistent reduce left-ventricular ejection fraction ) . In patient stable angina pectoris , Ranolazine use beneficial results1 . Ranolazine improve diastolic blood flow therefore microcirculation myocardium reduce diastolic tension ( via inhibit late Na+-Influx consecutive Ca2+-Overload ) . Recently publish data2 show treatment Ranolazine significantly reduce ischemic area chronic damage myocardium . This due effect improve microcirculation hibernate myocardium . Early administration Ranolazine improvement microcirculation patient acute damage myocardium ( i.e . directly acute ischemia ) lead recruitment re-uptake cardiac activity hibernate myocardium . For RIMINI-Trial patient give Ranolazine top guideline-based treatment reduce area acute ischemic myocardium . Patients unstable angina pectoris proof acute cardiac ischemia , proof myocardial dyskinesia angina pectoris patient history receive unaltered guideline-based therapy acute cardiac ischemia5,6 . All necessary procedure perform stabilize patient hemodynamically compensated state patient transfer receive cardiac catheterization ( angiography angioplasty necessary ) . After patient stabilized Ranolazine give additionally guideline base medication . The measurement ischemic myocardial area do via three functional echocardiography speckle track technique10 . A statistical evaluation ischemic myocardial area treatment Ranolazine/Placebo do conclusion RIMINI-Trial show effect Ranolazine acute myocardial ischemia .</brief_summary>
	<brief_title>Reduction Ischemic Myocardium With Ranolazine-Treatment Patients With Acute Myocardial Ischemia</brief_title>
	<detailed_description>The aim RIMINI-Trial examine effect Ranolazine ischemic myocardium acute myocardial ischemia . A pilot-trial Venkatamaran et al . recently demonstrate , area ischemic myocardium patient stable coronary artery disease reduce Ranolazine-treatment2 . This effect show significantly reduce area atypical dysfunctional myocardium SPECT-examinations . The dimension myocardial damage ( i.e . area ischemic myocardium ) directly relate : 1 . Rate complication ( i.e . left-ventricular pump failure , malignant arrhythmia ) 2 . Grade Rehabilitation daily life ( i.e . persistent reduce left-ventricular ejection fraction ) Early angioplasty coronary medication key factor prevent complication ensure sufficient rehabilitation . This do reduce ischemic area best possible . In patient stable angina pectoris , Ranolazine use beneficial results1 . Ranolazine improve diastolic blood flow therefore microcirculation myocardium reduce diastolic tension ( via inhibit late Na+-Influx consecutive Ca2+-Overload ) . Recently publish data2 show treatment Ranolazine significantly reduce ischemic area chronic damage myocardium . This due effect improve microcirculation hibernate myocardium . Early administration Ranolazine improvement microcirculation patient acute damage myocardium ( i.e . directly acute ischemia ) lead recruitment re-uptake cardiac activity hibernate myocardium . For RIMINI-Trial patient give Ranolazine top guideline-based treatment reduce area acute ischemic myocardium . Patients unstable angina pectoris proof acute cardiac ischemia ( Serum level Troponin-T-hs &gt; 14 pg/ml ) , proof myocardial dyskinesia angina pectoris &gt; /=CCS II ( Canadian Cardiovascular Society Classification Angina Pectoris ) patient history receive unaltered guideline-based therapy acute cardiac ischemia5,6 . All necessary procedure perform stabilize patient hemodynamically compensate state ( normalized level blood pressure , heart rate , absent malignant arrhythmia , dyspnoea angina-like symptom ) , patient transfer receive cardiac catheterization ( angiography angioplasty necessary ) . After patient stabilize ( i.e . via angioplasty , medical treatment ) Ranolazine give additionally guideline-based medication ( Beta-Blocker , ACE-Inhibitor AT1-Inhibitor , ASS , Clopidogrel , Statins ) . The measurement ischemic myocardial area do via three functional echocardiography speckle track technique10 ( speckle -tracking echocardiography , SPE ) : 1 . The first speckle track screen do directly patient present emergency room . 2 . After stabilization coronary angiography -plasty first dose Ranolazine give , second speckle track do baseline . 3 . After 42 day Ranolazine-treatment third final speckle track echocardiography do . A statistical evaluation ischemic myocardial area treatment Ranolazine/Placebo do conclusion RIMINI-Trial show effect Ranolazine acute myocardial ischemia . For control compare effect , RIMINI-Trial single-blinded compare group patient treat Ranolazine . Participants randomize treatment-group no-treatment-group use computer base randomization-method .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Proof acute cardiac ischemia elevate serum Troponin Ths level &gt; 14 pg/nl Proof myocardial dyskinesia functional echocardiography ( `` speckle track '' ) Stable angina pectoris &gt; /= CCS II patient history Stabilized ( i.e . normalized vital parameter ) patient coronary angioplasty angiography Coronary angioplasty angiography old 24 hour Written inform consent Established standard therapy coronary artery disease ( i.e . BetaBlocker , ACEInhibitor AT1Inhibitor , ASS , Clopidogrel , Statins ) Patients young 18 year age Acute cardiopulmonary decompensation Middle high grade liver insufficiency ( ChildPugh Score B C ) High grade renal insufficiency ( CreatinineClearance &lt; 30 ml/min ) Concomitant treatment potent inhibitor CYP3A4 Concomitant administration class Ia ( e.g . quinidine ) class III ( e.g . dofetilide , sotalol ) antiarrhythmic , except amiodarone Concomitant administration &gt; 20 mg simvastatin/day Patients heart failure classification NYHA III NYHA IV Homeless patient drugaddicted patient Pregnant and/or breastfeed woman Treatment Ranolazine prior enrolment RIMINITrial Allergy Ranolazine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>ischemia</keyword>
	<keyword>myocardium</keyword>
	<keyword>Ranolazine</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>speckle track echocardiography</keyword>
</DOC>